Semaglutide / Metformin

Capsule

3 mg / 100 mg |  7 mg / 100 mg  |  14 mg / 100 mg

Ready to prescribe?
Disclaimer: Images are for reference only; actual products may vary.

Product Overview Coming Soon

Product Overview

Semaglutide Description1-6

Semaglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) that functions as an incretin mimetic. Incretins are hormones released from the gastrointestinal tract into the systemic circulation that support glycemic control and have been utilized in weight management. When administered orally, semaglutide is indicated for the following use:

  • Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

Data indicate that oral semaglutide may produce clinically meaningful outcomes for individuals seeking weight reduction. In a 68-week study, oral semaglutide was associated with an average weight decrease of approximately 15%.

 

Metformin Description7-9 

Metformin is an oral biguanide used to improve glycemic control in adult and pediatric patients 10 years and older with type 2 diabetes mellitus (T2DM). The drug is often 1st line for patients with T2DM. The drug is indicated for

  • For treatment of type 2 diabetes mellitus as an adjunct to diet and exercise

There is evidence that metformin facilitates weight loss and decreases the appetite of patients who are administered the drug.

 

References

  1. Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
  2. Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
  3. Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
  4. Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  5. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
  6. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719. https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
  7. Metformin package insert https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
  8. Clinical Pharmacology metformin clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  9. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019 Jun;8(2):156-164.

Semaglutide1-6

Semaglutide is an incretin mimetic that works on the glucagon-like peptide-1 (GLP-1) receptor by binding and activating the GLP-1 receptor. It has 94% sequence homology to human GLP-1. GLP-1 medications regulate glucose metabolism after oral consumption of carbohydrates and fats. The drug increases insulin secretion by glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose levels. It also suppresses glucagon secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation.

 

Metformin7-9 

As an antidiabetic medication, metformin reduces gluconeogenesis production in the liver, decreases absorption of glucose in the gastrointestinal tract, and increases insulin sensitivity and subsequently peripheral glucose uptake and utilization. The drug facilitates glucose utilization in skeletal and adipose tissue. Metformin is believed to facilitate weight loss by decreasing caloric intake by patients through gastrointestinal adverse effects and appetite is decreased by production of glucagon like peptide 1 production.

Common 3,4,7-9

Gastrointestinal: Nausea, vomiting, diarrhea, constipation, dyspepsia, headache, dizziness.

Contraindications & Precautions3,4,7-9

Contraindications:

  • Hypersensitivity to semaglutide or metformin or its components
  • In people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with multiple endocrine neoplasia syndrome type 2 (semaglutide)
  • In patients who are pregnant
  • In patients with chronic metabolic acidosis, including diabetic ketoacidosis (metformin)

Precautions:

  • In patients with a history of pancreatitis and gall bladder disease (semaglutide)
  • In patients with renal and hepatic impairment
  • Store at controlled room temperature (20°C to 25°C / 68°F to 77°F)
  • Protect from moisture and light
  • Keep in a tightly closed container
  1. Semaglutide (Ozempic) Prescribing Information – Novo Nordisk https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf. Revised December 2017. Accessed May 27, 2025
  2. Semaglutide (Wegovy) Prescribing Information Novo Nordisk www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf. Revised July 2023. Accessed June 22, 2025
  3. Semaglutide (Rybelsus) Prescribing Information https://www.novo-pi.com/rybelsus.pdf December 2024. Accessed June 22, 2025
  4. Clinical Pharmacology semaglutide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  5. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019 Apr 12;10:155.
  6. Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, Rubino DM, Garvey WT; OASIS 1 Investigators. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 26;402(10403):705-719. https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
  7. Metformin package insert https://packageinserts.bms.com/pi/pi_glucophage_xr.pdf
  8. Clinical Pharmacology metformin clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  9. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019 Jun;8(2):156-164.
This information is for educational purposes only.
This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.
This information is a summary. It may not cover all possible drug information about this product. For complete product information, refer to the manufacturer’s prescribing information and labeling. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088. A WP Pharma Labs pharmacist will be happy to answer any questions. For consultation, please call 1-800-441-0048.

EXPLORE MORE

Related Medications

Licensed to ship across the U.S.

Your orders arrive promptly and privately, delivered directly to your door.

Providers: Let’s Partner for Better Patient Care

If you are a physician, clinic, or practice seeking a dependable Compounding Pharmacy partner, WP Pharma Labs is here to help. With dedicated account setup, streamlined ordering and responsive service, we support your therapeutic goals with specialized compounds designed for your patients.

To check product availability, check on the status of an existing order, request refills:
orders@wppharmalabs.com

New providers setup / update an existing account:
newaccounts@wppharmalabs.com